[HTML][HTML] Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M-mutated NSCLC that had progressed after prior EGFR tyrosine kinase inhibitor …
S Lu, Y Zhang, G Zhang, J Zhou, S Cang… - Journal of Thoracic …, 2022 - Elsevier
Abstract Introduction Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase
inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or …
inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or …
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy …
S Lu, Y Zhang, G Zhang, J Zhou, S Cang… - Journal of Thoracic …, 2022 - jto.org
Abstract Introduction Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase
inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or …
inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or …
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy …
S Lu, Y Zhang, G Zhang, J Zhou… - Journal of thoracic …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor
(TKI). This study evaluated befotertinib in patients with locally advanced or metastatic …
(TKI). This study evaluated befotertinib in patients with locally advanced or metastatic …